-

Theramex Launches Non-hormonal Femarelle® on the 12th of May

LONDON--(BUSINESS WIRE)--Theramex will be joining the 20th International Society of Gynecological Endocrinology (ISGE) congress from the 11th-14th May in Florence, Italy. The ISGE is a non-profit organization whose purpose is to drive more awareness around important gynecology topics ensuring a dialogue between interested parties.

Theramex are very proud to introduce Femarelle® which Theramex will commercialize in Italy, France, Spain, Germany, UK, Belgium, Poland and Australia. Femarelle® is a non-hormonal food supplement developed to help women manage symptoms in perimenopause, with Femarelle® Rejuvenate1; menopause, with Femarelle® Recharge2; and post-menopause, with Femarelle® Unstoppable3.

At Theramex we are committed to supporting women throughout their different stages in life, offering a host of options to suit their specific health needs along the way. As many women with menopause symptoms do not currently use HRT treatment, but instead are choosing lifestyle changes to cope with them, Femarelle® could be another option for these women.

As Camilla Harder Hartvig, Chief Commercial Officer at Theramex says "we are delighted to add Femarelle® to our already broad portfolio of prescription products to treat menopause symptoms. We are all about giving women choices so that they can take charge themselves and through these choices continue to live life uninterrupted".

About Theramex

Theramex is a leading global specialty pharmaceutical company dedicated to women and their health. We support women at every stage of their lives by providing a broad portfolio of innovative and established brands covering contraception, fertility, menopause and osteoporosis. Our commitment is to listen to and understand our patients, serve their needs and offer healthcare solutions to help improve their lives. Our vision is to be a lifetime partner for women and the healthcare professionals who treat them by providing patient-focused and effective solutions that care for and support women through every stage of life.

1 Femarelle® Rejuvenate package leaflet.
2 Femarelle® Recharge package leaflet.
3 Femarelle® Unstoppable package leaflet.

Contacts

Camilla Harder Hartvig
CommunicationsPR@Theramex.com

Industry:

Theramex

Release Versions
EnglishSpanish (Summary)GermanFrenchItalian (Summary)Dutch (Summary)

Contacts

Camilla Harder Hartvig
CommunicationsPR@Theramex.com

Social Media Profiles
Theramex Global
More News From Theramex

Theramex Announces Agreement to Acquire the European Rights to Duphaston® and Femoston® From Viatris, Inc.

LONDON--(BUSINESS WIRE)--Theramex, a leading global speciality pharmaceutical company dedicated to women’s health, is pleased to announce that it has entered into an agreement to acquire the European rights to Duphaston® and Femoston® from Viatris Inc. Viatris retains the rights for Australia and Japan. The transaction is subject to customary regulatory and anti-trust approvals. “As we continue to strengthen our commitment to women’s health and improve our patients access to high quality treatm...

Theramex Enters Into an Exclusive Licensing Agreement With Radius Health Inc, to Commercialise ELADYNOS® ▼in the European Economic Area, the United Kingdom, Australia and Brazil

LONDON--(BUSINESS WIRE)--Theramex, a leading global speciality pharmaceutical company dedicated to women’s health, has entered into an exclusive licensing agreement with Radius Health, Inc., for the rights to commercialise ELADYNOS® (abaloparatide), a novel bone forming agent indicated for the treatment of osteoporosis in postmenopausal women at increased risk of fractures. Theramex will commercialise and distribute ELADYNOS® on an exclusive basis in the European Economic Area, the United Kingd...

Theramex Announces European Commission Marketing Authorization for Yselty® (linzagolix), an Oral GnRH Antagonist, for the Treatment of Symptoms of Uterine Fibroids

LONDON--(BUSINESS WIRE)--The European Commission (EC) has granted Marketing Authorization for Yselty® (linzagolix), an oral GnRH antagonist, indicated for the treatment of moderate to severe symptoms of Uterine Fibroids (UF) in adult women (over 18 years of age) of reproductive age. This announcement is in partnership with ObsEva SA (Nasdaq: OBSV), a biopharmaceutical company developing and commercializing novel therapies for women’s health. The EC decision follows the Committee for Medicinal P...
Back to Newsroom